ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Open access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 3 pooled it
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 3 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Efficacy and safety of natural killer cell therapy for the treatment of advanced non-small cell lung cancer: A meta-analysis and systematic review.Immunologic research · 2025Pooled it
- Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.Targeted oncology · 2024Pooled it
- Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.Journal of hematology & oncology · 2025Trial
- Ex vivo-expanded and activated haploidentical natural killer cells infusion before autologous stem cell transplantation in high-risk neuroblastoma: a phase I/II pilot study.Cancer immunology, immunotherapy : CII · 2025Trial
- Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.Oncoimmunology · 2026Article
- Next-generation natural killer cell therapy: bench to bedside and beyond.Signal transduction and targeted therapy · 2026Review
- Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective Treatment.Cancers · 2026Review
- The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing.Frontiers in immunology · 2026Article
- Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.Advances in experimental medicine and biology · 2026Review
- Natural killer cells in adoptive cell therapy: current landscape of genetic engineering strategies.Oncoimmunology · 2025Review
- Microvascular Ultrasound Imaging in the Neonatal Brain: From Advanced Doppler to Super-Resolution.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2025Review
- In Vitro Expansion and Transduction of Primary NK Cells Using Feeder Cells Expressing Costimulatory Molecules and IL-21.Cancer science · 2025Article
- Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Sara M FedericoDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. sara.federico@stjude.org.
M Beth McCarvilleDepartment of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Barry L ShulkinDepartment of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Paul M SondelDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin, Madison, Wisconsin.
Jacquelyn A HankDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin, Madison, Wisconsin.
Paul HutsonDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin, Madison, Wisconsin.
Michael MeagherDepartment of Therapeutics Production and Quality, St. Jude Children's Research Hospital, Memphis, Tennessee.
Aaron ShaferDepartment of Therapeutics Production and Quality, St. Jude Children's Research Hospital, Memphis, Tennessee.
Catherine Y NgDepartment of Therapeutics Production and Quality, St. Jude Children's Research Hospital, Memphis, Tennessee.
Wing LeungDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
William E JanssenHuman Applications Lab, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jianrong WuDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Shenghua MaoDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Rachel C BrennanDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Victor M SantanaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Alberto S PappoDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Wayne L FurmanDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
St. Jude Children's Research Hospital · USUniversity of Wisconsin–Madison · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MXENOGRAFT STUDIESP01CA023099 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HOUGHTON, PETER J · 1985 to 2011
$22.4MNCI NIH HHS P01 CA023099NCI NIH HHS P30 CA021765
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell- and Tissue-Based TherapyAdolescentAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCarboplatinChildChild, PreschoolCombined Modality TherapyCyclophosphamideDacarbazineDisease-Free SurvivalDrug-Related Side Effects and Adverse ReactionsEtoposideFemaleGangliosidesAntibodies, Monoclonal, HumanizedCamptothecinCarboplatinCyclophosphamideDacarbazineEtoposideGangliosidesIfosfamideIL2 protein, humanIL2RA protein, humanInterleukin-2Interleukin-2 Receptor alpha SubunitIrinotecansialogangliosidesTemozolomideTopotecan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.